Impurity analysis is an important part of biologic drug manufacturing because biological products can contain unwanted substances arising from production processes, raw materials, or product degradation. These impurities may include residual host cell proteins, DNA, aggregates, and other process-related or product-related substances. Analytical testing helps manufacturers identify, characterize, and monitor impurities throughout development and production. Understanding impurity analysis provides insight into biologic product quality, manufacturing consistency, and patient safety. Different analytical techniques are selected according to the product, impurity characteristics, and quality requirements established during development and manufacturing.
Biologic medicines are produced using living cells or biological systems, making their manufacturing processes more complex than those used for many conventional small molecule drugs. Products such as monoclonal antibodies, recombinant proteins, and certain vaccines require careful monitoring because variations in biological processes can affect product composition. Impurity analysis helps identify unwanted materials and evaluate whether manufacturing processes consistently produce products that meet established quality specifications.
Impurities in biologic medicines can originate from raw materials, production systems, purification steps, storage conditions, or changes in the biological product itself. Identifying their sources is essential for developing suitable controls and understanding their potential effects on product quality.
Impurities are generally classified as process-related or product-related. Process-related impurities arise during manufacturing, whereas product-related impurities are associated with the biological molecule or its degradation.
Common impurity categories include:
Host cell proteins: Proteins produced by the cells used to manufacture a biologic may remain in the product if purification does not remove them adequately.
Residual host cell DNA: Small amounts of genetic material from production cells may persist after purification and require appropriate monitoring.
Process-related residues: Substances such as residual culture components, purification reagents, or processing chemicals may need to be assessed and controlled.
Protein aggregates: Biologic molecules can associate into larger structures during manufacturing, handling, or storage. Aggregation may affect product stability and potentially influence immune responses.
Degradation products: Changes such as oxidation, deamidation, fragmentation, or other molecular modifications can occur during processing or storage.
Product variants: Differences in molecular structure, including certain charge or glycosylation variants, may influence product characteristics and require evaluation according to their relevance.
Not every detected impurity presents the same level of concern. Its significance depends on its identity, concentration, biological activity, potential toxicity, and the characteristics of the specific medicine. Manufacturers therefore establish impurity limits and acceptance criteria using scientific evidence, product knowledge, and applicable regulatory expectations.
Impurity analysis uses multiple analytical methods because biologic medicines are structurally complex and impurities can differ substantially in size, chemical properties, and biological activity. No single method can detect every possible impurity, so testing strategies often combine complementary techniques.
Common analytical approaches include:
High performance liquid chromatography: HPLC separates components in a sample according to their interactions with a stationary phase and mobile phase. Different configurations can help assess purity, degradation products, and molecular variants.
Mass spectrometry: This technique measures mass-to-charge ratios and can help identify or characterize proteins, peptides, and other molecular components.
Size exclusion chromatography: SEC separates molecules based largely on their size in solution and is frequently used to evaluate protein aggregates and fragments.
Enzyme linked immunosorbent assays: ELISA methods can quantify specific impurities, including host cell proteins, when suitable antibodies and validated procedures are available.
Polymerase chain reaction methods: PCR-based techniques can detect and quantify residual DNA sequences when the assay is appropriately designed and validated.
Electrophoretic methods: Techniques such as capillary electrophoresis can help separate proteins or other charged components and evaluate product-related differences.
Biological activity assays: Functional testing can help determine whether a biologic retains its expected biological activity, complementing structural impurity measurements.
Analytical procedures must be appropriate for their intended use and supported by suitable validation or qualification. Important performance characteristics may include accuracy, precision, specificity, sensitivity, and quantitation limits.
Quality control also extends beyond laboratory testing. Manufacturers use process monitoring, equipment controls, validated purification procedures, stability studies, and documented investigations of unexpected results. Regulatory guidance from organizations such as the International Council for Harmonisation helps inform impurity assessment, analytical validation, and quality management throughout product development and manufacturing.
A scientifically justified impurity control strategy combines knowledge of the manufacturing process with reliable analytical evidence. This approach supports consistent product quality and helps manufacturers evaluate changes in raw materials, production conditions, purification performance, and storage over the biologic medicine's lifecycle.